Category: 23687-25-4

Synthetic Route of 23687-25-4, A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 23687-25-4, Name is Isoquinolin-4-amine, molecular formula is C9H8N2. In a Article£¬once mentioned of 23687-25-4

Palladium-catalyzed coupling of ammonia and lithium amide with aryl halides

A mild, palladium-catalyzed coupling of aryl halides with ammonia or lithium amide to form primary arylamines as the major product is described. These reactions occurred with excellent selectivity for formation of the primary arylamine over formation of the diarylamine (9.5:1 to over 50:1 ratios of arylamine to diarylamine). In addition, the first organopalladium complex with a terminal -NH2 ligand has been isolated. This complex reductively eliminates to form arylamines. Copyright

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Synthetic Route of 23687-25-4. In my other articles, you can also check out more blogs about 23687-25-4

Reference£º
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

In heterogeneous catalysis, the catalyst is in a different phase from the reactants. Safety of Isoquinolin-4-amine, At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 23687-25-4, name is Isoquinolin-4-amine. In an article£¬Which mentioned a new discovery about 23687-25-4

Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability

Pharmacological activation of NRF2 (nuclear factor erythroid 2-related factor 2) arises from blocking the interaction of NRF2 with its negative regulator, KEAP1 (Kelch-like ECH-associated protein 1). We previously reported an isoquinoline-based NRF2 activator, but this compound showed negative logD7.4 and a-2 charge at physiological pH, which may have limited its membrane permeability. In this work, we report potent, metabolically stable analogs that result from replacing a carboxymethyl group at the 4-position with a fluoroalkyl group.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 23687-25-4, help many people in the next few years.Safety of Isoquinolin-4-amine

Reference£º
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Reference of 23687-25-4, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.23687-25-4, Name is Isoquinolin-4-amine, molecular formula is C9H8N2. In a Patent£¬once mentioned of 23687-25-4

Peptide deformylase inhibitors

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 23687-25-4

Reference£º
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

In heterogeneous catalysis, the catalyst is in a different phase from the reactants. Product Details of 23687-25-4, At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 23687-25-4, name is Isoquinolin-4-amine. In an article£¬Which mentioned a new discovery about 23687-25-4

6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists

A series of N-[{2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)-pyridin-3-yl}methyl] N?-(6,6-fused heterocyclic) ureas have been investigated as hTRPV1 antagonists. Among them, compound 15 showed highly potent TRPV1 antagonism to capsaicin, with Ki(ant) = 0.2 nM, as well as antagonism to other activators, and it was efficacious in a pain model. A docking study of 15 with our hTRPV1 homology model indicates that there is crucial hydrogen bonding between the ring nitrogen and the receptor, contributing to its potency.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 23687-25-4, help many people in the next few years.Product Details of 23687-25-4

Reference£º
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

23687-25-4, Isoquinolin-4-amine is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

23687-25-4, General procedure: To a solution of 3 (100 mg, 0.18 mmol) in dry DCM (10 mL), oxalyl chloride (70 mg, 0.55 mmol), triethylamine (3 mg, 0.03 mmol) and DMF (2 mg, 0.03 mmol) were added, and the mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure, the residue was dissolved in dry THF (1 * 10 mL), the solvent was removed, and the residue was immediately dissolved in dry DCM (10 mL). The solution was cooled to 0 C and triethylamine (24 mg, 0.24 mmol), DMAP (2 mg, 0.02 mmol) as well as 3-aminopyridine (52 mg, 0.55 mmol) were added. After 2 days of stirring, Et2O (100 mL) was added, the organic was washed with diluted HCl (0.1 m, 1 * 100 mL), water (2 * 100 mL) and brine (1 * 50 mL), dried (MgSO4), filtrated and evaporated to dryness. Column chromatography (silica gel, hexane/ethyl acetate, 7:3) afforded 5 (85 mg, 75%) as a white solid; 4.2.242alpha, 3beta, 24-Triacetyloxy-ursan-12-en-28-oic acid 4-isoquinolinyl amide (28) As described for 5, compound 28 (53 mg, 44%) was obtained from 25 and 4-aminoisoquinoline as a white solid; m. p. 173-177 C; RF = 0.40 (silica gel, chloroform/ethyl acetate, 1:1); [alpha]D = -0.85 (c = 0.33, CHCl3); UV-vis (CHCl3): lambdamax (log epsilon) = 289 nm (3.68), 301 nm (3.67), 324 nm (3.72); IR (KBr): nu = 3396 m, 2948 m, 2926 m, 2870 m, 1746vs, 1684 m, 1626w, 1586w, 1522 m, 1488 m, 1456 m, 1370s, 1252vs, 1044 s cm-1; 1H NMR (500 MHz, CDCl3): delta = 9.08 (s, 1 H, H-38), 9.03 (s, 1 H, H-39), 8.00 (d, J = 8.2 Hz, 1 H, H-41), 7.91 (m, 1 H, NH), 7.77-7.72 (m, 2 H, H-44 + H-42), 7.63 (ddd, J = 8.0, 5.9, 2.0 Hz, 1 H, H-43), 5.56 (dd, J = 3.4, 3.4 Hz, 1 H, H-12), 5.14 (ddd, J = 10.5, 10.5, 4.5 Hz, 1 H, H-2), 5.07 (d, J = 10.3 Hz, 1 H, H-3), 3.82 (d, J = 11.8 Hz, 1 H, H-24a), 3.57 (d, J = 11.8 Hz, 1 H, H-24b), 2.22 (d, J = 10.1 Hz, 1 H, H-18), 2.15 (ddd, J = 13.6, 13.6, 4.2 Hz, 1 H, H-16a), 2.10-1.91 (m, 5 H, H-1a + H-11a + H-11b + H-22a + H-16b), 2.08 (s, 3 H, H-36), 2.01 (s, 3 H, H-34), 1.98 (s, 3 H, H-32), 1.86 (ddd, J = 14.4, 14.4, 4.4 Hz, 1 H, H-15a), 1.77 (ddd, J = 13.6, 13.6, 4.3 Hz, 1 H, H-22b), 1.69 (dd, J = 11.0, 6.6 Hz, 1 H, H-9), 1.62 (ddd, J = 13.3, 6.6, 3.2 Hz, 1 H, H-21a), 1.59-1.52 (m, 1 H, H-19), 1.50-1.28 (m, 6 H, H-7a + H-7b + H-21b + H-6a + H-6b + H-5), 1.20-1.04 (m, 3 H, H-15b + H-1b + H-20), 1.17 (s, 3 H, H-27), 1.02 (d, J = 6.3 Hz, 3 H, H-30), 1.00 (s, 3 H, H-25), 0.97 (d, J = 6.5 Hz, 3 H, H-29), 0.85 (s, 3 H, H-23), 0.73 (s, 3 H, H-26) ppm; 13C NMR (125 MHz, CDCl3): delta = 176.8 (C-28), 170.9 (C-35), 170.6 (C-31), 170.5 (C-33), 149.5 (C-39), 140.2 (C-13), 137.6 (C-38), 130.5 (C-42), 130.0 (C-37), 128.9 (C-40), 128.5 (C-41), 128.3 (C-45), 127.4 (C-43), 126.0 (C-12), 120.1 (C-44), 74.9 (C-3), 70.0 (C-2), 65.4 (C-24), 54.7 (C-18), 49.5 (C-17), 47.7 (C-5), 47.7 (C-9), 43.9 (C-1), 42.8 (C-14), 42.1 (C-4), 40.1 (C-19), 39.8 (C-8), 39.3 (C-20), 37.9 (C-10), 37.8 (C-22), 32.5 (C-7), 31.0 (C-21), 28.0 (C-15), 25.2 (C-16), 23.6 (C-11), 23.5 (C-27), 21.3 (C-30), 21.2 (C-32), 21.0 (C-36), 20.9 (C-34), 17.9 (C-6), 17.4 (C-26), 17.4 (C-29), 17.2 (C-25), 14.0 (C-23) ppm; MS (ESI): m/z (%) = 741.5 ([M+H]+, 100), 763.3 ([M+Na]+, 4), 1482.3 ([2 M + H]+, 92); analysis calculated for C45H60N2O7 (740.97): C 72.94, H 8.16, N 3.78; found: C 72.75, H 8.33, N 3.52.

The synthetic route of 23687-25-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Sommerwerk, Sven; Heller, Lucie; Kuhfs, Julia; Csuk, Rene; European Journal of Medicinal Chemistry; vol. 122; (2016); p. 452 – 464;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23687-25-4,Isoquinolin-4-amine,as a common compound, the synthetic route is as follows.

23687-25-4, Example 2282-(cyclopentanecarboxamido)-N-(isoquinolin-4-yl)isonicotinamideIn a 5 mL round-bottom flask was dissolved 2-(cyclopentanecarboxamido)isonicotinic acid (36 mg, 0.154 mmol) and isoquinolin-4-amine (26.6 mg, 0.184 mmol) in dimethylformamide (0.8 mL) to give a tan solution. HATU (117 mg, 0.307 mmol) and Hunig’sBase (0.054 mL, 0.307 mmol) were added, and the mixture was stirred at rt overnight for 19 h. The desired product was obtained by prep-HPLC (5.9 mg, 10%): MS (ESI) (m/z): 361 (M+H)+; 1H NMR (400 MHz, DMSO) delta 10.81 (s, IH), 10.67 (s, IH), 9.32 (s, IH), 8.69 (s, IH), 8.65 (s, IH), 8.59 – 8.51 (m, IH), 8.30 – 8.20 (m, IH), 8.07 – 7.99 (m, IH), 7.91 – 7.84 (m, IH), 7.82 – 7.74 (m, IH), 7.73 – 7.66 (m, IH), 3.05 – 2.98 (m, IH), 1.95 – 1.85 (m, 2H), 1.83 – 1.66 (m, 4H), 1.64 – 1.54 (m, 2H).

As the paragraph descriping shows that 23687-25-4 is playing an increasingly important role.

Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; LUO, Guanglin; CHEN, Ling; DUBOWCHIK, Gene M.; JACUTIN-PORTE, Swanee E.; SIVAPRAKASAM, Prasanna; MACOR, John E.; WO2015/69593; (2015); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23687-25-4,Isoquinolin-4-amine,as a common compound, the synthetic route is as follows.,23687-25-4

To a stirring solution of 4-aminoisoquinoline (1.4 g, 10.0 mmol) in 5 N aqueous hydrochloric acid (12 mE) at 00 C. was added a solution of sodium nitrite (NaNO2, 0.069 g, 10.0 mmol) in deionized water (1 mE), while maintaining the internal temperature below 00 C. The reaction mixture was stirred at 00 C. for 30 mm and a solution of tin(II) chloride dihydrate (SnC12.2H20, 5.6 g, 25.0 mmol) dissolved in concentrated hydrochloric acid (5 mE) was added dropwise. The mixture was stirred at room temperature for 2 h and the solution was adjusted to pH -12-14 with 20% aqueous sodium hydroxide. The mixture was extracted with 2:1 CHC13/iPrOH. The organic layer was dried (Na2SO4), filtered, and concentrated in vacuo. The resulting crude product was purified by flash chromatography (Si02, 50% ethyl acetate in hexanes) to give the desired compound (0.84 g, 5.3 mmol, 53%)

As the paragraph descriping shows that 23687-25-4 is playing an increasingly important role.

Reference£º
Patent; ChemoCentryx, Inc.; Cappel, Markus; (83 pag.)US2018/9797; (2018); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23687-25-4,Isoquinolin-4-amine,as a common compound, the synthetic route is as follows.

Example 17 N-(1-Methyl-5-indolyl)-N’-(4-isoquinolyl) urea (E17) The title compound was prepared from 4-aminoisoquinoline, 1,1′-carbonyl diimidazole and 5-amino-1-methyl-indole using a procedure similar to that described for Example 1, and then converted to the hydrochloride salt using hydrogen chloride in ether/ethanol, in 26% overall yield, m.p. 195-197 C., 23687-25-4

The synthetic route of 23687-25-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SmithKline Beecham, p.l.c.; US5508288; (1996); A;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23687-25-4,Isoquinolin-4-amine,as a common compound, the synthetic route is as follows.,23687-25-4

Isoquinolin-4-amine (50 mg, 0.347 mmol), phenyl (4-methyl-3-(l-methyl-6- oxo-l,6-dihydropyridin-3-yl)-l-phenyl-lH-pyrazol-5-yl)carbamate (Intermediate 5, 99.2 mg, 0.248 mmol) and NEt3 (104 mu, 0.743 mmol) were combined in DMF (0.2 mL) and stirred ambient temperature overnight. The mixture was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-70% acetonitrile/water, to afford the title compound (52 mg, 0.115 mmol, 47% yield). MS (apci) m/z = 451.2 (M+H).

The synthetic route of 23687-25-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ARRAY BIOPHARMA INC.; ALLEN, Shelley; BLAKE, James F.; BRANDHUBER, Barbara J.; JIANG, Yutong; KOLAKOWSKI, Gabrielle R.; XU, Rui; WINSKI, Shannon L.; WO2014/78328; (2014); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem